Gambia vs Tajikistan: HIV/AIDS deaths averted by antiretroviral therapy
Gambia
883.72 deaths
in 2024
Tajikistan
827.83 deaths
in 2024
Gambia rank
77th
Tajikistan rank
79th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Gambia
- Tajikistan
How they compare
Gambia currently reports 883.72 deaths against 827.83 deaths in Tajikistan, a difference of 55.89 deaths.
That makes Gambia's figure about 1.1 times Tajikistan's.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Tajikistan ahead.
Gambia ranks 77th and Tajikistan ranks 79th of 157 countries.
Gambia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Gambia | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 59.36 deaths | 10.42 deaths | 48.94 deaths | Gambia |
| 2010s | 595.79 deaths | 340.73 deaths | 255.06 deaths | Gambia |
| 2020s | 789.23 deaths | 755.08 deaths | 34.15 deaths | Gambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Gambia or Tajikistan?
- Gambia, at 883.72 deaths against 827.83 deaths in Tajikistan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Gambia and Tajikistan?
- 55.89 deaths, with Gambia ahead.
- How many years of comparable data are there for Gambia and Tajikistan?
- 35 years are reported by both, from 1990 to 2024.
- How do Gambia and Tajikistan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Gambia ranks 77th and Tajikistan ranks 79th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.